All medications are a double-edged sword with risks
|
|
- Lee Sharp
- 5 years ago
- Views:
Transcription
1 Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: /gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone therapy in clinical perspective Howard N. Hodis, MD, and Wendy J. Mack, PhD Abstract Although many of the risks and benefits of postmenopausal hormone therapy are known, only recently has the magnitude of these effects and their perspective to other therapies become more fully understood. Careful review of randomized controlled trials indicates that the risks of postmenopausal hormone therapy including breast cancer, stroke and venous thromboembolism are similar to other commonly used agents. Overall, these risks are rare (less than 1 event per 1,000 women) and even rarer when initiated in women less than 60 years of age or within 10 years of menopause. In addition, the literature indicates similar benefit of postmenopausal hormone therapy, in women who initiate hormone therapy in close proximity to menopause, to other medications used for the primary prevention of coronory heart disease in women. Key Words: Hormone therapy Y Statin therapy Y Cardiovascular disease Y Breast cancer Y Stroke Y Venous thromboembolism. All medications are a double-edged sword with risks and benefits. Most medications enter the marketplace and become standard therapy without formal risk-benefit analyses. Hormones for postmenopausal hormone therapy are no exception. Putting medications and standard therapies into clinical perspective is perhaps the most common approach to understanding overall utility and reasonable acceptance of risks and benefits. The benefits of hormone therapy are well appreciated. The risks of most concern are breast cancer, stroke, and venous thrombosis. Any single randomized, controlled trial does not provide complete information for determination of risks and benefits. This is especially true for hormones because certain effects are similar for most postmenopausal hormone therapies, whereas other effects depend on specific medications, doses, regimens, and routes of administration. This fact is apparent in regard to the divergent effects of hormone therapy on breast cancer, in which case oral daily continuous combined conjugated equine estrogens (CEE) + medroxyprogesterone acetate (MPA) was associated with an increased risk of breast cancer 1 and oral CEE was associated with a decreased risk of breast cancer. 2 Received July 17, 2006; revised and accepted November 9, From the Departments of Medicine and Preventive Medicine and the Atherosclerosis Research Unit, Keck School of Medicine, University of Southern California, Los Angeles, CA. Funding/support: Funded by the National Institute on Aging (R01-AG24154). Financial disclosure: None reported. Address correspondence to: Howard N. Hodis, MD, Keck School of Medicine, Atherosclerosis Research Unit, 2250 Alcazar Street, CSC 132, Los Angeles, CA athero@usc.edu. After the initial sensationalism of the first few randomized, controlled trials of hormone therapy and coronary heart disease, 3 more tempered critical reappraisals of the cumulating randomized, controlled trial data in relation to the totality of data have emerged. 4 This apparent Bflip-flopping^ is partly due to the fact that assessment of risks and benefits is a dynamic process with very few unambiguous certitudes. As such, viewing the cumulated randomized, controlled trial data of coronary heart disease benefit and potential side effects of postmenopausal hormone therapy in light of other therapies, such as those for the primary prevention of coronary heart disease, is both important and enlightening. CORONARY HEART DISEASE As they are for men, lipid-lowering medications, predominantly 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins), are the mainstay for primary prevention of coronary heart disease in women. 5,6 However, the cumulated data across six randomized trials and 11,435 women do not provide strong support for the use of these medications for primary prevention of coronary heart disease in women 7 : relative risk (RR) = 0.87 (95% CI: 0.69<1.09) for coronary heart disease events; RR = 0.61 (95% CI: 0.22<1.68) for nonfatal myocardial infarction; RR = 0.95 (95% CI: 0.62<1.46) for total mortality; and RR = 1.07 (95% CI: 0.47<2.40) for coronary heart disease mortality. In the final analysis, data supporting the use of lipid-lowering medication for the reduction of coronary heart disease in women and on which to base recommendations for primary prevention are limited compared to that of men. 7 Recommendations for using lipid-lowering medications in the primary prevention of coronary heart disease in women are Menopause, Vol. 14, No. 5,
2 HODIS AND MACK predominantly extrapolated from data derived from men and from secondary prevention trials in women. 5,6 In contrast, the cumulated data across 23 randomized, controlled trials of 39,049 women followed for 191,340 patient-years indicate a 32% (odds ratio [OR] = 0.68, 95% CI: 0.48<0.96) reduction of coronary heart disease in women younger than 60 years old or less than 10 years since menopause when randomized to hormone therapy relative to placebo. 8 This compares to an OR for coronary heart disease of 0.99 (95% CI: 0.88<1.11) for all women and 1.03 (95% CI: 0.91<1.16) for women more than 60 years old or more than 10 years since menopause when randomized to hormone therapy relative to placebo. 8 Hormone therapy is associated with significantly lower relative risk of coronary heart disease events in younger women compared to older women (OR = 0.66, 95% CI: 0.46<0.95). 8 In addition, the cumulated data indicate a 39% (OR = 0.61, 95% CI: 0.39<0.95) reduction in overall mortality in women younger than 60 years old who were randomized to hormone therapy relative to placebo. 9 Oral daily CEE mg therapy under primary prevention conditions in the Women s Health Initiative (WHI)- estrogen (E) trial reduced several composite coronary heart disease outcomes by approximately 34% to 45% in 3,310 postmenopausal women younger than 60 years old 10 (Table 1). In addition, both the Heart and Estrogen/progestin Replacement Study (HERS) (P for trend = 0.009) and the WHIestrogen + progestin (EP) trial (P for trend = 0.02) indicate that increasing duration of oral daily continuous combined CEE mg + MPA 2.5 mg therapy reduces the risk of coronary heart disease. 11,12 There is also consistency between the WHI observational study and the WHI-EP and WHI-E randomized, controlled trials in that coronary heart disease risk was reduced with more than 5 years of CEE + MPA therapy and CEE therapy, respectively 13,14 (Table 2). Results from the WHI-EP have also shown a reduction (P for trend = 0.036) of coronary heart disease according to time since menopause; women randomized within 10 years of menopause had a reduction in coronary TABLE 1. Number (annualized percentage) of coronary heart disease (CHD) events with conjugated equine estrogens (CEE) or placebo in 50- to 59-year-old women at baseline from the Women s Health Initiative estrogen trial CHD event Placebo (n = 1,673) CEE (n = 1,637) HR (95% CI) CHD (MI or CD) 34 (0.27) 21 (0.17) 0.63 (0.36<1.08) Angina a 35 (0.28) 21 (0.17) 0.59 (0.34<1.02) CABG or PCI 52 (0.42) 29 (0.24) 0.55 (0.35<0.86) MI, CD, CABG, 65 (0.52) 42 (0.35) 0.66 (0.44<0.97) and PCI MI, CD, CABG, PCI, and angina a 70 (0.56) 46 (0.38) 0.66 (0.45<0.96) HR, hazard ratio; CABG, coronary artery bypass grafting; CD, coronary heart disease death; MI, nonfatal myocardial infarction; PCI, percutaneous coronary intervention. a Angina pectoris confirmed with hospitalization for angina and confirmatory stress test or coronary artery disease by angiography. TABLE 2. Hazard ratios for coronary heart disease in the Women s Health Initiative clinical trials and observational study according to duration of use of estrogen + progestin and estrogen alone a Clinical trial Observational study Duration of use (y) Hazard ratio b (95% CI) Hazard ratio c (95% CI) CEE + MPA 13 G (1.15<2.45) 1.12 (0.46<2.74) 2< (0.87<1.79) 1.05 (0.70<1.58) (0.36<1.21) 0.83 (0.67<1.01) CEE alone 14 G (0.68<1.68) 1.20 (0.49<2.94) 2< (0.79<1.61) 1.09 (0.75<1.60) (0.57<1.12) 0.73 (0.61<0.84) CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate. a Adjusted for age, race, body mass index, educational level, smoking, age at menopause, and physical activity. b Relative to placebo. c Relative to nonusers of hormone therapy. heart disease (hazard ratio [HR] = 0.89), whereas women 10 to 19 years beyond menopause (HR = 1.22) and more than 20 years beyond menopause (HR = 1.71) had increased risk. 15,16 These latter results are consistent with the divergent effects seen at the arterial wall level, where oral 17Aestradiol therapy slowed the progression of atherosclerosis in relatively healthy arteries but had no effect on diseased arteries. 17,18 In contrast to lipid-lowering therapy for the primary prevention of coronary heart disease, the cumulated data indicate that in certain women (younger than 60 years old or within 10 years of menopause), hormone therapy reduces coronary heart disease and overall mortality. Initiation of hormone therapy close to rather than remote from menopause seems to be key in the full expression of the cardioprotective effects of hormone therapy. 8,9 Conversely, in specific trials, certain risks of lipid-lowering medications, such as breast cancer, resemble those of CEE + MPA reported from the WHI-EP. BREAST CANCER The breast cancer results from the WHI starkly contrast; CEE alone was associated with a reduction in breast cancer risk, 2 whereas CEE + MPA was associated with an increased risk. 1 In the WHI-EP trial, the RR for breast cancer was increased 24% with oral daily continuous combined CEE + MPA therapy, resulting in nine additional cases of breast cancer per 10,000 women per year of CEE + MPA therapy 1 (Table 3). Overall mortality and mortality due to breast cancer did not differ between CEE + MPA therapy and placebo. A more recent analysis from the WHI-EP with adjustment for breast cancer risk factors indicates a 20% (RR = 1.20, 95% CI: 0.94<1.53) increased risk of breast cancer associated with CEE + MPA therapy. 19 The elevated breast cancer risk in the WHI-EP was limited to those women who used postmenopausal hormone therapy before the WHI-EP trial. 19 In HERS, CEE + MPA therapy (same 2 Menopause, Vol. 14, No. 5, 2007 * 2007 The North American Menopause Society
3 POSTMENOPAUSAL HORMONE THERAPY IN CLINICAL PERSPECTIVE TABLE 3. Comparison of absolute and relative risks of breast cancer in randomized, controlled trials of postmenopausal hormone and statin therapies Study No. of breast cancers (annualized %) Placebo Therapy RR 95% CI No. of additional breast cancer cases per 10,000 women per year of therapy Statin PROSPER (0.23) 18 (0.38) < AFCAPS/TexCAPS 22 9 (0.35) 13 (0.50) S 10-y follow-up 23 5 (0.11) 7 (0.17) < CARE 21 1 (0.07) 12 (0.84) < LIPID (0.22) 10 (0.22) < ALLHAT-LLT (0.30) 34 (0.28) <1.48 j2 HPS (0.40) 38 (0.30) <1.13 j10 CEE + MPA WHI-EP (0.33) 199 (0.42) <1.59 a 9 HERS (0.45) 32 (0.57) < CEE alone WHI-E (0.42) 129 (0.34) <1.04 j8 b 17A-E 2 alone WEST 24 5 (0.55) 5 (0.53) <3.50 j2 RR, relative risk; Statin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor; PROSPER, Prospective Study of Pravastatin in the Elderly Risk; AFCAPS/TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; 4S, Scandinavian Simvastatin Survival Study; CARE, Cholesterol and Recurrent Events Trial; LIPID, Long-Term Intervention with Pravastatin in Ischaemic Disease; ALLHAT-LLT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; HPS, Heart Protection Study; CEE + MPA, oral daily continuous combined conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg); WHI-EP, Women s Health Initiative estrogen + progestin trial; HERS, Heart and Estrogen/progestin Replacement Study; CEE alone, oral daily conjugated equine estrogens (0.625 mg); WHI-E, Women s Health Initiative estrogen trial; 17A-E 2, oral daily 17A-estradiol (1 mg); WEST, Women s Estrogen for Stroke Trial. a Adjusted 95% CI describes the variability of the point estimate corrected for multiple outcome analyses. Unadjusted 95% CI describes the variability of the point estimate that would arise from a simple trial for a single outcome; for conjugated equine estrogens + medroxyprogesterone acetate therapy, this interval is 1.01<1.54. b Total breast cancer incidence statistically significantly reduced in conjugated equine estrogens versus placebo in adherent subjects (hazard ratio [HR] = 0.67, 95% CI: 0.47<0.97). Statistically significant reduction of ductal (most common) breast cancer in subjects randomized to conjugated equine estrogens versus placebo (HR = 0.71, 95% CI: 0.52<0.99). See Stefanick et al. 2 hormone therapy as in the WHI-EP) was associated with an increased risk of breast cancer 11 (Table 3). Although these trials show that the risk of breast cancer associated with oral CEE + MPA therapy is rare and, at most, of borderline significance, these facts do not negate the importance of considering a medication that may cause breast cancer. However, CEE + MPA is not the only commonly used medication associated with a possible increase in breast cancer risk. Such comparisons bring into focus the clinical perspective of the breast cancer risk of oral daily CEE + MPA therapy relative to other commonly used medications and preventive therapies. In the Prospective Study of Pravastatin in the Elderly Risk (PROSPER), a 3.2-year randomized, controlled trial of pravastatin versus placebo in men and women 70 to 82 years old, the diagnosis of new cancer was increased by 25% (HR = 1.25, 95% CI: 1.04<1.51), or approximately 52 additional cancer cases per 10,000 persons per year of pravastatin use. 20 The effect of pravastatin on cardiovascular events in 3,000 women was null (HR = 0.96, 95% CI: 0.79<1.18). The risk of breast cancer was increased 65% (RR = 1.65, 95% CI: 0.78<3.49) in women randomized to pravastatin (18 events) relative to placebo (11 events). This pravastatin-associated breast cancer risk (annualized rate of 0.38%) is similar to the breast cancer risk seen in the WHI- EP (annualized rate of 0.42%), or 15 additional cases of breast cancer per 10,000 womenperyearofpravastatin use (Table 3). The CI for the risk of breast cancer with pravastatin in PROSPER was wider than that in the WHI-EP because the sample size in PROSPER was 5.5 times smaller. The elevated risk of breast cancer associated with the use of pravastatin was reported in an additional randomized, controlled trial of 576 women 59 T 9yearsold treated for 5 years, 21 in 997 postmenopausal women 55 to 73 years old treated with lovastatin for 5.2 years, 22 and in 827 women 60.5 T 6.4yearsoldfollowedfor5yearsafter randomized treatment to simvastatin for 5.4 years. 23 In the Cholesterol and Recurrent Events (CARE) trial, there were 12 cases of breast cancer in women randomized to pravastatin and 1 case in a woman randomized to placebo, or approximately 77 additional cases of breast cancer per 10,000 women per year of pravastatin use 21 (Table 3). In the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), there were 13 cases of breast cancer in women randomized to lovastatin and 9 cases in women randomized to placebo, or approximately 15 additional cases of breast cancer per 10,000 women per year of lovastatin use 22 (Table 3). In the 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S), there were seven cases of breast cancer in women randomized to simvastatin and five cases in women randomized to placebo, or five additional cases of breast cancer per 10,000 women per year of simvastatin use 23 (Table 3). Because breast cancer events were not reported in the original 5.4-year intervention trial and the subsequent 5-year follow-up period was open-label, the incidence of breast cancer solely due to Menopause, Vol. 14, No. 5,
4 HODIS AND MACK simvastatin exposure cannot be completely determined from the information provided from this study. However, the greater number of breast cancer events in the simvastatintreated versus placebo-treated group in open-label followup suggests a possible residual breast cancer risk from simvastatin. 23 The 15 to 77 additional cases of breast cancer per 10,000 women per year of statin use compares to the 9 additional cases of breast cancer per 10,000 women per year of CEE + MPA therapy in the WHI-EP and the 12 additional cases of breast cancer per 10,000 women per year of CEE + MPA therapy in the HERS (Table 3). The increased absolute risk of breast cancer seen with statin therapy contrasts with CEE alone. In the WHI-E trial, breast cancer was decreased 18% with CEE therapy relative to placebo (HR = 0.82, 95% CI: 0.65<1.04), resulting in eight fewer cases of breast cancer per 10,000 women per year of CEE therapy 2 (Table 3). In subgroup analyses, breast cancer risk was further reduced in women adherent to CEE therapy relative to placebo (HR = 0.67, 95% CI: 0.47<0.97) and in women who developed the most common form of breast cancer, ductal carcinoma (HR = 0.71, 95% CI: 0.52<0.99). In the Women s Estrogen for Stroke Trial (WEST), hormone therapy with 17A-estradiol alone also resulted in a fewer number of absolute cases of breast cancer relative to placebo 24 (Table 3). In addition, the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) trial showed no difference in breast cancer risk between pravastatin and placebo, 25 the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) 26 showed 2 fewer cases of breast cancer per 10,000 women per year of pravastatin use, and the Heart Protection Study (HPS) showed 10 fewer breast cancer cases per 10,000 women per year of simvastatin use 27 (Table 3). Unlike the WHI-EP, in which colorectal cancer risk was reduced with CEE + MPA therapy relative to placebo, gastrointestinal cancer risk was increased by 46% with pravastatin treatment relative to placebo in PROSPER (RR = 1.46, 95% CI: 1.00<2.13; 22 additional cases of gastrointestinal cancer per 10,000 persons per year of pravastatin use). 20 In the WHI-EP, colorectal cancer was reduced 37% with CEE + MPA therapy relative to placebo (HR = 0.63, 95% CI: 0.43<0.92), resulting in six fewer cases of colorectal cancer per 10,000 women per year of CEE + MPA therapy. 12 Although lipid-lowering trials other than PROSPER have not shown statistically significant increased risk of cancer overall, the overall absolute cancer risk in the primary prevention trials with statins that have reported cancer incidence is consistently elevated. 22,26 The overall absolute cancer risk specifically determined in women in the primary prevention trial AFCAPS/TexCAPS was elevated, with approximately 15 additional cases of cancer per 10,000 women per year of lovastatin use. 22 In the primary prevention trial ALLHAT-LLT, the overall absolute cancer risk was five additional incident cases of cancer and seven additional cancer deaths per 10,000 persons per year of pravastatin use. 26 Sitespecific cancer incidence, especially breast cancer incidence, has not been reported in all lipid-lowering randomized, controlled trials, and thus the breast canceryrelated risk remains unknown across all lipid-lowering medications. 28,29 A recent meta-analysis reported data from five randomized, controlled trials of statin therapy (PROSPER, CARE, 4S, LIPID, ALLHAT-LLT), indicating a 33% (OR = 1.33, 95% CI: 0.79<2.26) increased risk of breast cancer associated with statin use. There were 81 cases of breast cancer per 27,112 women-years in women randomized to statin therapy and 64 cases of breast cancer per 27,462 women-years in women randomized to placebo, or 7 additional breast cancer cases per 10,000 women per year who used statin therapy. 28 A previous meta-analysis reporting data from seven randomized, controlled trials of statin therapy (Table 3) showed a 4% (RR = 1.04, 95% CI: 0.81<1.33) increased risk of breast cancer associated with statin use. There were 132 cases of breast cancer cases per 42,412 women-years in women randomized to statin therapy and 124 cases of breast cancer per 42,757 women-years in women randomized to placebo, or 2 additional breast cancer cases per 10,000 women per year who used statin therapy. 29 Although the oncogenicity of statins and other lipid-lowering medications is complex, incompletely understood, and controversial, there is biological plausibility for induction of cancer in general and for breast cancer specifically. 30<32 In the final analysis, the cumulated data indicate that the absolute risk of breast cancer associated with statin therapy and oral daily continuous combined CEE + MPA therapy as seen in the WHI-EP and HERS is low and similar: j1 to 7.7 additional breast cancers per 1,000 women per year of statin therapy versus 0.9 to 1.2 additional breast cancers per 1,000 women per year of CEE + MPA therapy (Table 3). In contrast to the limited effect of lipid-lowering therapy in reducing coronary heart disease under primary prevention conditions, 7 early initiation of CEE + MPA within 10 years of menopause and duration of CEE + MPA therapy of more than 5 years reduced the risk of coronary heart disease. 8,9,11,13,15,16 Statin and CEE + MPA therapies contrast with oral CEE alone, which was associated with a reduced breast cancer risk in the WHI-E 2 and, in certain women (younger than 60 years old), a reduced risk of coronary heart disease. 8<10 STROKE Although WEST has been the only randomized, controlled trial of hormone therapy designed with stroke as the primary trial outcome, 24 HERS and WHI have also provided information concerning hormone therapy and stroke as an additional trial outcome. WEST was a randomized, controlled trial designed to test whether oral 17A-estradiol 1 mg/day reduces the combined outcome of nonfatal stroke or all-cause mortality in 664 postmenopausal women who were, on average, 71 years old and approximately 20 years postmenopausal at baseline. 24 The women had a documented nondisabling stroke or 4 Menopause, Vol. 14, No. 5, 2007 * 2007 The North American Menopause Society
5 POSTMENOPAUSAL HORMONE THERAPY IN CLINICAL PERSPECTIVE transient ischemic attack within 90 days of randomization into the trial. As such, WEST was a trial that assessed the effect of 17A-estradiol on the secondary prevention of stroke. Deaths from all causes or nonfatal stroke occurred in 99 participants in the estradiol group and in 93 participants in the placebo group (RR = 1.1, 95% CI: 0.8<1.4). There were 51 nonfatal strokes in the estradiol group and 52 nonfatal strokes in the placebo group (RR = 1.0, 95% CI: 0.7<1.4) and 12 fatal strokes in the estradiol group and 4 fatal strokes in the placebo group (RR = 2.9, 95% CI: 0.9<9.0). There were 48 deaths from all causes in the estradiol group and 41 deaths in the placebo group (RR = 1.2, 95% CI: 0.8<1.8). There were no increased rates of venous thromboembolism (VTE) or breast cancer in the estradiol compared to the placebo group (Tables 3 and 7). The cumulated randomized, controlled trial results concerning stroke and hormone therapy are mixed (Table 4), consistent with previous observational studies that show decreased risk, 13,14,33<36 no effect, 37<40 and increased risk, at least among smokers. 41 WEST showed that oral 17Aestradiol had a null effect on the secondary prevention of nonfatal stroke and nonfatal and fatal stroke combined. 24 HERS showed that oral daily continuous combined CEE + MPA had little effect on nonfatal stroke in postmenopausal women with established coronary heart disease. 42 The WHI- EP 12,43 and WHI-E 44,45 showed that nonfatal stroke was positively associated with oral CEE + MPA and CEE alone (Table 4). Combined stroke followed the same pattern as nonfatal stroke in both the WHI-EP 12,43 and WHI-E. 44,45 The case numbers of fatal strokes in these trials were small and thus difficult to interpret. Although the cumulated data do not conclusively indicate that hormone therapy significantly increases stroke relative to placebo, the randomized, controlled trials do indicate a consistent increase in the point estimate of risk with hormone therapy relative to placebo. The number of additional cases of stroke associated with hormone therapy is greater in women with preexisting coronary heart disease or stroke (ranging from 27 to 56 additional cases per 10,000 women per year of hormone therapy use across randomized, controlled trials) than in women in whom the majority did not have preexisting cardiovascular disease (ranging from 7 to 12 additional cases per 10,000 women per year of hormone therapy use across randomized, controlled trials) (Table 4). In the WHI-EP, the number of additional cases of stroke per 10,000 women per year of CEE + MPA therapy was lower for women younger than 60 years old versus older than 60 years old (4 vs 22 additional cases of stroke per 10,000 women per year of CEE + MPA therapy) and lower for women randomized within 5 years of menopause than for those randomized more than 5 years after menopause (3 vs 22 additional cases of stroke per 10,000 women per year of CEE + MPA therapy). For women randomized within 5 years, between 5 and less than 10 years, between 10 and less than 15 years, or more than 15 years since menopause, the number of additional cases of stroke were rare, with less than one additional stroke per 1,000 women per year of CEE + MPA therapy 43 (Table 5). In the WHI-E, the number of additional cases of stroke per 10,000 women per year of CEE therapy was lower for women younger than 60 years old versus older than 60 years old (1 vs 39 additional cases of stroke per 10,000 women per year of CEE therapy) and lower for women randomized within 10 years of menopause than for those randomized more than 10 years after menopause (15 vs 25 additional cases of stroke per 10,000 women per year of CEE therapy). For women younger than 60 years of age when randomized, the number of additional cases of stroke was rare, with less than one additional stroke per 10,000 women per year of CEE therapy 45 (Table 5). The age- and time-related stroke data from the WHI are important in that they indicate that the number of additional cases of stroke is rare (less than one per 1,000 women per year of hormone therapy) for CEE + MPA therapy in women less than 5 years from menopause and for CEE therapy in women younger than 60 years old (Table 5). Data from the Nurses Health Study indicate that stroke risk associated with hormone therapy may be a function of estrogen dose. 46 Prophylactic use of aspirin for primary prevention of coronary heart disease is a common medical practice and recommended by major health organizations. 5 However, the Women s Health Study (WHS) of 39,876 healthy women randomized to aspirin 100 mg every other day or placebo for 10 years showed a null effect of aspirin on the primary trial endpoint of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death (RR = 0.91, 95% CI: 0.80<1.03). 47 Overall mortality and cardiovascular death from any cause were also unaffected by aspirin. Within the null finding was no effect on fatal or nonfatal myocardial infarction (RR = 1.02, 95% CI: 0.84<1.25) and a 17% (RR = 0.83, 95% CI: 0.69<0.99) reduction in stroke with aspirin relative to placebo, or two fewer strokes per 10,000 women per year of aspirin use. Although ischemic stroke was reduced 24% (RR = 0.76, 95% CI: 0.63<0.93) with aspirin relative to placebo, hemorrhagic stroke was also increased 24% (RR = 1.24, 95% CI: 0.82<1.87) with aspirin relative to placebo (Table 4). Bleeding diatheses, not seen with hormone therapy, were all significantly increased with aspirin versus placebo in the WHS. 47 Any gastrointestinal bleeding was increased 22% (RR = 1.22, 95% CI: 1.10<1.34) with aspirin versus placebo, and gastrointestinal bleeding requiring blood transfusion was increased 40% (RR = 1.40, 95% CI: 1.07<1.83) with aspirin versus placebo. The absolute increased risk of any gastrointestinal bleeding was eight additional cases per 10,000 women per year of aspirin use. The other randomized, controlled trials of aspirin that included women were of smaller size and shorter duration than WHS but showed similar magnitudes of risk with no overall reduction in cardiovascular events (Hypertension Optimal Treatment [HOT]: n = 8,883 women, 3.8 years 48, and Primary Prevention Project [PPP]: n = 2,583 women, 3.6 years 47,49 ). Meta-analyses confirm the same or greater levels of risks of bleeding diatheses and hemorrhagic stroke for men, in whom Menopause, Vol. 14, No. 5,
6 HODIS AND MACK TABLE 4. Comparison of absolute and relative risks of stroke in randomized, controlled trials of postmenopausal hormone therapy and other medications Trial Sample size Mean age, y Cohort Study duration, y No. of additional combined strokes per 10,000 women per year of therapy Combined stroke, RR (95% CI) Fatal stroke, RR (95% CI) Nonfatal stroke, RR (95% CI) Ischemic stroke, RR (95% CI) Hemorrhagic stroke, RR (95% CI) Aspirin WHS 47 39, jcvd 10.0 j (0.69<0.99) 1.04 (0.58<1.86) 0.81 (0.67<0.97) 0.76 (0.63<0.93) 1.24 (0.82<1.87) Tamoxifen NSABP 53 13, jcvd (0.93<2.77) 1.34 a NR 1.63 a NR 1.51 a NR 1.67 a NR Raloxifene RUTH 54 10, TCHD (0.92<1.32) 1.49 ( ) f NR 1.15 (0.93<1.41) 0.59 (0.33<1.06) CEE + MPA WHI-EP 43 16, jcvd (1.02<1.68) b (0.93<1.84) c 1.20 d (0.58<2.50) d (0.32<4.49) d 1.50 d (1.08<2.08) d 1.44 (1.09<1.90) (0.83<2.70) d adjusted NR 0.82 (0.43<1.56) adjusted NR HERS 42 2, CHD (0.89<1.70) 1.61 (0.73<3.55) 1.18 (0.83<1.66) 1.18 (0.83<1.67) 1.65 (0.47<5.72) CEE alone WHI-E 45 10, jcvd (1.09<1.73) (0.97<1.99) e 1.13 e (0.54<2.34) e (0.38<3.36) e 1.39 e (1.05<1.89) e 1.55 (1.19<2.01) (0.91<2.12) e adjusted NR 0.64 (0.35<1.18) adjusted NR 17A-estradiol alone WEST CVA/TIA (0.80<1.60) 2.90 (0.90<9.00) 1.00 (0.70<1.40) 1.00 (0.6<1.4) 1.30 (0.3<6.0) RR, relative risk; WHS, Women s Health Study; NSABP, National Surgical Adjuvant Breast and Bowel Project; RUTH, Raloxifene Use for the Heart; WHI-EP, Women s Health Initiative estrogen + progestin trial; HERS, Heart and Estrogen/progestin Replacement Study; WHI-E, Women s Health Initiative estrogen trial; WEST, Women s Estrogen for Stroke Trial; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate; NR, not reported; Combined stroke, nonfatal + fatal stroke; jcvd, no previous cardiovascular disease; +CHD, previous coronary heart disease; +CVA/TIA, previous cerebrovascular accident or transient ischemic attack. a Relative risk (95% CI) not reported. Relative risk calculated from data given in reference. Placebo: 3 fatal strokes, 21 nonfatal strokes, 14 ischemic strokes, 6 hemorrhagic strokes; tamoxifen: 4 fatal strokes, 34 nonfatal strokes, 21 ischemic strokes, 10 hemorrhagic strokes. b Unadjusted CI describes the variability of the point estimate that would arise from a simple trial for a single outcome. c Adjusted CI describes the variability of the point estimate corrected for multiple outcome analyses. d Fully adjudicated data not reported in reference 43. Data shown in table are the original partially adjudicated data from reference 12. e Fully adjudicated data not reported in reference 45. Data shown in table are the original partially adjudicated data from reference 44. f Mosca L, Grady D, Barrett-Connor E, et al. Risk of stroke in the Raloxifene Use for The Heart (RUTH) trial. Circulation 2006;114(Suppl2): Menopause, Vol. 14, No. 5, 2007 * 2007 The North American Menopause Society
7 POSTMENOPAUSAL HORMONE THERAPY IN CLINICAL PERSPECTIVE TABLE 5. Absolute risk of stroke according to age and years since menopause when randomized to the Women s Health Initiative trials Absolute risk no. of strokes per 10,000 women per year Placebo (n = 8,102) WHI-EP 43 CEE + MPA (n = 8,506) No. of additional cases of stroke per 10,000 women per year of therapy Years since menopause G toG to G Age, y 50< < < Placebo (n = 5,429) WHI-E 45 CEE (n = 5,310) Years since menopause G to Age, y 50< < < WHI-EP, Women s Health Initiative estrogen + progestin trial; WHI-E, Women s Health Initiative estrogen trial; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate. the data are more substantial because the majority of study participants in the randomized, controlled trials of aspirin have been men. 50 Sudden death was increased in men randomized to aspirin versus placebo. In the Physicians Health Study (PHS) (n = 22,071), there were 22 sudden deaths in the men randomized to aspirin and 12 events in men randomized to placebo (OR = 1.96, 95% CI: 0.91<4.23), or an increased absolute risk of five sudden deaths per 10,000 men per year of aspirin use. 51 Whether aspirin causes sudden death in women is unknown because these data were not reported in WHS, HOT, or PPP. The magnitude of the side effects associated with aspirin resembles those from CEE + MPA and CEE from the WHI. 12,44 Other medications such as tamoxifen and raloxifene are similarly associated with increased incidence of stroke. 52 In the National Surgical Adjuvant Breast and Bowel Project (NSABP) trial of 13,388 women, the incidence of stroke increased from 24 events in the placebo group to 38 events in the tamoxifen group (RR = 1.59, 95% CI: 0.93<2.77). 53 This RR equates to 9 cases of stroke per 10,000 women per year of placebo use versus 14 cases of stroke per 10,000 women per year of tamoxifen use, or approximately 5 additional cases of stroke per 10,000 women per year of tamoxifen use. In a 5.6-year clinical trial of 10,101 postmenopausal women, the incidence of stroke increased from 79 events per 10,000 women per year in the placebo group to 88 events per 10,000 women per year in the raloxifene group (RR = 1.10, 95% CI: 0.92<1.32), or 9 additional cases of stroke per 10,000 women per year of raloxifene use. 54 After 3 years of use, raloxifene was associated with an increased risk of fatal stroke compared with placebo (RR = 1.49, 95% CI: ) (Table 4). The RR of stroke seen with tamoxifen and raloxifene is comparable to that seen with postmenopausal hormone therapy, and, like with postmenopausal hormone therapy, the absolute risk is of small magnitude in the primary prevention setting (Table 4). It is of interest to examine stroke subtypes by various interventions as reported in the literature (Table 6). Under primary prevention conditions, hormone therapy seems to have a pattern of increasing the risk of ischemic stroke while decreasing the risk of hemorrhagic stroke. Whereas ischemic stroke risk was increased 44% in the WHI-EP, hemorrhagic stroke risk associated with oral daily continuous combined CEE + MPA therapy relative to placebo was reduced 18%. 43 TABLE 6. Comparison of absolute and relative risks of ischemic and hemorrhagic stroke among various therapies Trial Therapy Ischemic stroke, RR (95% CI) Hemorrhagic stroke, RR (95% CI) Primary WHI-EP 43 CEE + MPA 44% j18% 1.44 (1.09<1.90) 0.82 (0.43<1.56) WHI-E 45 CEE 55% j36% 1.55 (1.19<2.01) 0.64 (0.35<1.18) WHS 47 Aspirin j24% 24% 0.76 (0.63<0.96) 1.24 (0.82<1.87) HPS 27 Statin j30% j30% 0.7 (0.5<0.8) 0.7 (0.4<1.2) Secondary HERS 42 CEE + MPA 18% 65% 1.18 (0.83<1.67) 1.65 (0.47<5.72) WEST 24 17A-estradiol 0% 30% 1.0 (0.6<1.4) 1.3 (0.3<6.0) SPARCL 55 Statin j22% 66% 0.78 (0.66<0.94) 1.66 (1.08<2.55) HPS 27 Statin j20% 90% 0.8 (0.6<1.1) 1.9 (0.9<4.4) Absolute risk per 10,000 women per year Ischemic stroke Hemorrhagic stroke Primary WHI-EP 43 CEE + MPA 8 j1 WHI-E 45 CEE 13 j2 WHS 47 Aspirin j3 1 HPS 27 Statin j22 j3 Secondary HERS 42 CEE + MPA 18 5 WEST 24 17A-estradiol j37 9 SPARCL 55 Statin j48 19 HPS 27 Statin j28 13 RR, relative risk; WHI-EP, Women s Health Initiative estrogen + progestin trial; WHI-E, Women s Health Initiative estrogen trial; WHS, Women s Health Study; HPS, Heart Protection Study; HERS, Heart and Estrogen/ progestin Replacement Study; WEST, Women s Estrogen for Stroke Trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate; Statin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Menopause, Vol. 14, No. 5,
8 HODIS AND MACK TABLE 7. Comparison of absolute and relative risks of venous thromboembolism, deep vein thrombosis, and pulmonary embolism in randomized, controlled trials of postmenopausal hormone therapy and other medications Trial and outcome NSABP 53 Absolute risk events per 10,000 women per year No. of additional cases per 10,000 women per year of therapy RR (95% CI) Placebo Therapy Tamoxifen VTE NR NR NR < DVT 1.60 (0.91<2.86) PE 3.01 (1.15<9.27) RUTH 54 Raloxifene VTE 1.44 (1.06<1.95) DVT 1.37 (0.94<1.99) PE 1.49 (0.89<2.49) FIELD a66 Fenofibrate VTE NR NR NR < DVT b NR PE c NR WHI-EP 56 CEE + MPA VTE 2.06 (1.57<2.70) DVT 1.95 (1.43<2.67) PE 2.13 (1.45<3.11) HERS 62 CEE + MPA VTE 2.7 (1.4<5.0) DVT 2.8 (1.3<6.0) PE 2.8 (0.9<8.7) WHI-E 64 CEE alone VTE 1.32 (0.99<1.75) DVT 1.47 (1.06<2.06) PE 1.37 (0.90<2.07) WEST 24 17A-Estradiol alone VTE 0.8 (0.2<3.4) j12 DVT 0.5 (0.0<5.8) j11 PE 1.0 (0.1<7.1) j1 RR, relative risk; NSABP, National Surgical Adjuvant Breast and Bowel Project; RUTH, Raloxifene Use for the Heart; FIELD, Fenofibrate Intervention and Event Lowering in Diabetes; WHI-EP, Women s Health Initiative estrogen + progestin trial; HERS, Heart and Estrogen/progestin Replacement Study; WHI-E, Women s Health Initiative estrogen trial; WEST, Women s Estrogen for Stroke Trial; VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolus; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate; NR, not reported. a Cohort comprised 37% (n = 3,657) women. b Increased risk of deep vein thrombosis, P = c Increased risk of pulmonary embolism, P = In the WHI-E, ischemic stroke risk was increased 55%, whereas hemorrhagic stroke risk was reduced 36% in the oral CEE therapy group relative to placebo. 45 The pattern of hormone therapy in stroke risk contrasts with that of aspirin in the WHS, where a different pattern emerges. Although ischemic stroke risk was reduced 24%, the risk of hemorrhagic stroke was also increased 24% with aspirin therapy relative to placebo. 47 As HPS shows, statins seem to reduce both ischemic and hemorrhagic stroke risk under primary prevention conditions. In individuals with preexisting cardiovascular disease, hemorrhagic stroke risk compared to placebo seems to be elevated regardless of the therapy. In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, although ischemic stroke risk was reduced 22%, hemorrhagic stroke risk was increased 66% with statin therapy relative to placebo. 55 In HPS, hemorrhagic stroke risk was increased 90% with statin therapy relative to placebo. 27 Although hormone and nonhormone therapies tend to have statistically significant effects on the risk of stroke subtypes, absolute additional stroke protection or risk tends to be of a low magnitude, especially in individuals without preexisting cardiovascular disease (Table 6). VENOUS THROMBOEMBOLISM VTE is a disease process comprised of two different outcomes, deep vein thrombosis (DVT) and pulmonary embolism (PE). For DVT, there are two distinct clinical entities classified according to location: calf and other. Calf DVTs are considered clinically benign and typically are not treated because pathophysiologically they are rarely associated with PE. To date, the distinction between calf and other DVT locations associated with randomization in hormone therapy trials of cardiovascular disease have not been published. Although there was a two-fold greater risk of VTE in the CEE + MPA group relative to the placebo group in the WHI-EP, the increase in the absolute risk was small and comparable to that of other medications 56 (Table 7). The elevated absolute risk of VTE was lowest for women who were younger than 60 years old when randomized. For women younger than 60 years old, there were 11 additional cases of VTE per 10,000 women per year of CEE + MPA use versus 51 additional cases of VTE per 10,000 women per year of CEE + MPA use in women older than 60 years old 56 (Table 8). The increased risk of VTE was greatest in the first year after randomization and significantly decreased but remained elevated over time: the HR for VTE was 4.01 (CIs not reported) in year 1 of treatment, 1.97 in year 2, 1.74 in year 3, 1.70 in year 4, 2.90 in year 5, and 1.04 in year 6 and beyond (P for trend = 0.01). 56 This trend in the TABLE 8. Absolute and relative risks of venous thromboembolism in the Women s Health Initiative estrogen + progestin trial by age Age at screening, y Absolute risk per 10,000 women per year HR (95% CI) (relative to 50- to 59-year-old placebo group) 50<59 Placebo CEE + MPA (1.19<4.33) CEE + MPA vs placebo 11 a 2.27 b 60<69 Placebo (1.23<4.35) CEE + MPA (2.38<7.72) CEE + MPA vs placebo 16 a 1.85 b 70<79 Placebo (1.72<6.60) CEE + MPA (4.32<14.38) CEE + MPA vs placebo 35 a 2.21 b HR, hazard ratio; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate. a Number of additional cases of venous thromboembolism per 10,000 women per year of conjugated equine estrogens + medroxyprogesterone acetate therapy (difference of age-specific absolute risks). b Hazard ratio within each age group (ratio of age-specific hazard ratios). 8 Menopause, Vol. 14, No. 5, 2007 * 2007 The North American Menopause Society
9 POSTMENOPAUSAL HORMONE THERAPY IN CLINICAL PERSPECTIVE TABLE 9. Absolute and relative risks of deep vein thrombosis, pulmonary embolism, and venous thromboembolism in the Women s Health Initiative estrogen trial by age Deep vein thrombosis Pulmonary embolism Venous thromboembolism Age at screening, y Absolute risk per 10,000 women per year HR (95% CI) (relative to 50< to 59-year-old placebo group) Absolute risk per 10,000 women per year HR (95% CI) (relative to 50< to 59-year-old placebo group) Absolute risk per 10,000 women per year HR (95% CI) (relative to 50< to 59-year-old placebo group) 50<59 Placebo CEE (0.74<3.40) (0.63<3.77) (0.70<2.68) CEE vs placebo 5 a 1.64 b 4 a 1.54 b 4 a 1.37 b 60<69 Placebo (1.06<4.45) (0.70<3.78) (1.20<3.89) CEE (1.51<6.06) (1.28<6.16) (1.59<5.01) CEE vs placebo 6 a 1.39 b 7 a 1.72 b 7 a 1.31 b 70<79 Placebo (1.37<6.30) (1.12<6.39) (1.48<5.22) CEE (2.22<9.31) (0.96<5.80) (2.07<6.89) CEE vs placebo 12 a 1.54 b j2 a 0.88 b 11 a 1.36 b HR, hazard ratio; CEE = conjugated equine estrogens. a Number of additional cases of deep vein thrombosis, pulmonary embolism, or venous thromboembolism per 10,000 women per year of conjugated equine estrogens therapy (difference of age-specific absolute risks). b Hazard ratio within each age group (ratio of age-specific hazard ratios). reduction of VTE over time is consistent with those of previous observational studies, the majority of which suggest an early effect of postmenopausal hormone therapy on VTE limited to the first year of therapy and/or a decreasing risk of VTE over time. 13,14,57<61 In HERS, CEE + MPA was associated with a 2.7-fold increased risk of VTE relative to placebo 62 (Table 7). The increase in the absolute risk of VTE from CEE + MPA in HERS was greater than in the WHI-EP due to the greater baseline risk of VTE in HERS, a secondary prevention trial. Similar to the WHI-EP, over 6.8 years of follow-up, the HR for VTE declined from 2.66 during HERS 11,62 to 1.40 during the open-label follow-up of 2.7 years 63 (test for time trend, P =0.08). The results from the WHI-E showed a smaller RR of 1.32 (95% CI: 0.99<1.75) with respect to the risk of VTE with CEE alone relative to placebo 64 (Table 7). The absolute risk of VTE was lowest for women who were younger than 60 years old when randomized. For women younger than 60 years old, there were 4 additional cases of VTE per 10,000 women per year of CEE use versus 18 additional cases of VTE per 10,000 women per year of CEE use in women older than 60 years old (Table 9). Comparison of the results from the WHI-EP (HR = 2.1) and WHI-E (HR = 1.3) suggest that the VTE risk associated with CEE alone is less than the risk associated with CEE + MPA (62% increased risk associated with MPA relative to CEE alone). In the WEST, VTE and DVT were lower in the estradiol group relative to placebo, whereas there was no effect on PE 24 (Table 7). The cumulated data suggest that the increased risk of VTE associated with CEE + MPA is not generalizable to CEE alone or to other forms of estrogen. In a case-control study of 586 incident VTE cases and 2,268 controls, compared to women not currently using hormone therapy, current users of esterified estradiol alone, esterified estradiol + MPA, and CEE alone did not have an increased risk of VTE, whereas current users of CEE + MPA had a two-fold statistically significant increased risk of VTE 65 (Table 10). In combination with MPA, esterified estradiol (OR = 1.08) and CEE (OR = 2.17) had increased RRs of VTE, CEE + MPA was statistically significant (Table 10). The increased risk of VTE associated with CEE + MPA (OR = 2.17) in this casecontrol study was similar to the risk reported from the HERS (HR = 2.7) and WHI-EP (HR = 2.06). The risk of VTE associated with CEE alone (OR = 1.31) in this case-control study was similar to that of the WHI-E (HR = 1.32). Esterified estradiol alone (OR = 0.78) was also similar to estradiol alone in the WEST (RR = 0.8). Most studies of VTE risk in hormone users have been conducted in women using orally administered exogenous hormones. Theoretically, TABLE 10. Risk of venous thromboembolism with current use of different hormone therapies None EE alone EE + MPA CEE alone CEE + MPA No. of participants a Cases Controls 1, OR (95% CI) Reference 0.78 (0.53<1.15) 1.08 (0.75<1.56) 1.31 (0.91<1.88) 2.17 (1.49<3.14) OR 0.80 (WEST) 1.32 (WHI-E) 2.06 (WHI-EP) EE, esterified estrogen; MPA, medroxyprogesterone acetate; CEE, conjugated equine estrogens; OR, odds ratio; WEST, Women s Estrogen for Stroke Trial; WHI-E, Women s Health Initiative estrogen trial; WHI-EP, Women s Health Initiative estrogen + progestin trial. a Excludes 7 case and 25 control subjects who were current users of estrogens other than equine estrogen and conjugated equine estrogens. Menopause, Vol. 14, No. 5,
10 HODIS AND MACK nonoral routes of administration of hormone therapy should be associated with a lower risk of VTE than oral hormone therapy because of avoidance of the first-pass liver effects on procoagulation. However, the data are mixed, and this hypothesis has yet to be tested. 57,58,61 Although the data remain sparse, the effect of different hormones and regimens on VTE outcomes is intriguing and warrants further investigation. Other commonly used medications are also associated with elevated VTE risk. Both tamoxifen 53 and raloxifene 54 increase VTE by 1.4- to 3-fold. Like postmenopausal hormone therapy, the additional absolute risk tends to be small (Table 7). The added absolute risk of VTE from raloxifene (11 additional cases per 10,000 women per year of use) is similar to that of oral daily continuous combined CEE + MPA (18 additional cases per 10,000 women per year of use) and CEE alone in the WHI (8 additional cases per 10,000 women per year of use) but greater than the risk associated with 17A-estradiol alone (12 fewer cases per 10,000 women per year of use) (Table 7). The relative and absolute risks of PE associated with tamoxifen are greater than those associated with postmenopausal hormone therapy (Table 7). Fenofibrate (a fibric acid derivative used for lipid lowering) has also been shown to increase the risk of DVT and PE relative to placebo in diabetics, with seven additional DVTs per 10,000 subjects per year of fenofibrate use and nine additional PEs per 10,000 subjects per year of fenofibrate use 66 (Table 7). ADDITIONAL CONSIDERATIONS Other commonly used medications and supplements also exhibit risks comparable to or greater than those of postmenopausal hormone therapy. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was designed to assess the effect of fenofibrate on cardiovascular disease events in patients with type 2 diabetes mellitus. 66 This trial included 9,795 participants who were 50 to 75 years old; 37% of the participants were women. After 5 years of treatment, the primary endpoint of coronary events was nonsignificantly reduced in the fenofibrate group versus the placebo group (HR = 0.89, 95% CI: 0.75<1.05). This included a reduction in nonfatal myocardial infarction in the fenofibrate versus placebo group of 24% (HR = 0.76, 95% CI: 0.62<0.94) and an increase in coronary heart disease mortality of 19% (HR = 1.19, 95% CI: 0.90<1.57), resulting in seven additional coronary heart disease deaths per 10,000 participants per year of fenofibrate use. 66 Additionally, in the FIELD study, there were nine additional cancers per 10,000 subjects per year of fenofibrate use. In the FIELD study, although total cardiovascular disease events were reduced 11% (HR = 0.89, 95% CI: 0.80<0.99), total mortality was increased 11% (HR = 1.11, 95% CI: 0.95<1.29), resulting in 13 additional total deaths per 10,000 participants per year of fenofibrate use. 66 This same mixed pattern of an overall null effect on the primary endpoint of coronary events with a reduction in nonfatal myocardial infarction but an increase in total mortality of similar magnitude to that of the FIELD study has been reported with vitamin E supplementation in randomized, controlled trials. 67 The increased mortality seen with fenofibrate in the FIELD study and vitamin E in the Cambridge Heart Antioxidant Study (CHAOS) contrasts with certain subgroups receiving postmenopausal hormone therapy. In a meta-analysis of 30 randomized, controlled trials, women younger than 60 years old who were randomized to hormone therapy (a population of women similar to observational studies) had a 39% reduction in overall mortality relative to women randomized to placebo (OR = 0.61, 95% CI: 0.39<0.95), whereas in all women (OR = 0.98, 95% CI: 0.87<1.18) and in women older than 60 years old (OR = 1.03, 95% CI: 0.90<1.18), there was no difference in overall mortality. 9 Other commonly used products also demonstrating elevated risks have received little public health attention. In the Alpha- Tocopherol Beta-Carotene Cancer Prevention Study of 29,133 male smokers randomized for a median of 6.1 years, A-carotene increased the incidence of lung cancer by 18% (RR = 1.18, 95% CI: 1.03<1.36), resulting in nine additional lung cancers per 10,000 subjects per year of A-carotene use. 68 Overall mortality was also increased in the A-carotene group versus placebo group (RR = 1.08, 95% CI: 1.01<1.16) due to 5 additional lung cancer deaths, 8 additional ischemic heart disease deaths, 1.5 additional ischemic stroke deaths, and 1 additional hemorrhagic stroke death, each per 10,000 subjects per year of A-carotene use. 68 In subjects with previous myocardial infarction, fatal coronary heart disease death was increased in the A-carotene versus placebo group by 75% (RR = 1.75, 95% CI: 1.16<2.64), resulting in 146 additional fatal coronary heart disease deaths per 10,000 subjects per year of A-carotene use. 69 The results of the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study were confirmed in a second randomized, controlled trial (40% female) of A-carotene and retinol in 18,314 smokers, former smokers, and workers exposed to asbestos in the Beta- Carotene and Retinol Efficacy Trial (CARET). 70 After a mean follow-up of 4 years, subjects randomized to A-carotene and retinol had a 28% (RR = 1.28, 95% CI: 1.04<1.57) increase in lung cancer compared to the placebo group, resulting in 13 additional lung cancers per 10,000 subjects per year of A-carotene and retinol use. In the A-carotene and retinol group, the risk of death from lung cancer was increased 46% (RR = 1.46, 95% CI: 1.07<2.00) and the risk of death from cardiovascular disease was increased 26% (RR = 1.26, 95% CI: 0.99<1.61) compared to the placebo group. 70 Compared to the placebo group, death from any cause was increased 17% (RR = 1.17, 95% CI: 1.03<1.33) in the A-carotene and retinol group, resulting in 26 additional deaths per 10,000 subjects per year of A-carotene and retinol use. 70 Although conducted primarily in men, these studies demonstrate risk (without benefit) in a population at risk for lung cancer and cardiovascular disease from a commonly used supplement that exceeds that reported with postmenopausal hormone therapy. 10 Menopause, Vol. 14, No. 5, 2007 * 2007 The North American Menopause Society
CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationStatins are the most commonly used medications for
UPDATES ON AGING The Timing Hypothesis and Hormone Replacement Therapy: A Paradigm Shift in the Primary Prevention of Coronary Heart Disease in Women. Part 1: Comparison of Therapeutic Efficacy Howard
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationHORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
More informationNIH Public Access Author Manuscript Clin Obstet Gynecol. Author manuscript; available in PMC 2009 October 21.
NIH Public Access Author Manuscript Published in final edited form as: Clin Obstet Gynecol. 2008 September ; 51(3): 564 580. doi:10.1097/grf.0b013e318181de86. Postmenopausal Hormone Therapy and Cardiovascular
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationSupplementary Online Content
Supplementary Online Content Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationPhysicians and their women patients have. Assessing benefits and risks of hormone therapy in 2008: New evidence, especially with regard to the heart
HOWARD N. HODIS, MD Harry J. Bauer and Dorothy Bauer Rawlins Professor of Cardiology, Professor of Medicine and Preventive Medicine, Professor of Molecular Pharmacology and Toxicology, Director, Atherosclerosis
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationTHE WOMEN S HEALTH INITIAtive
ORIGINAL CONTRIBUTION JAMA-EXPRESS Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women Principal Results From the Women s Health Initiative Randomized Controlled Trial Writing
More informationThe preferred treatment for osteoporosis
Alternate Options to Hormone Replacement Therapy for Osteoporosis James R. Shoemaker, DO Andrea B. Klemes, DO This presentation, developed from a symposium lecture at the 40th Annual Convention of the
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationPostmenopausal hormones and coronary artery disease: potential benefits and risks
CLIMACTERIC 2007;10(Suppl 2):21 26 Postmenopausal hormones and coronary artery disease: potential benefits and risks R. A. Department of Obstetrics and Gynecology, Columbia University, New York, New York,
More informationWHI, HERS y otros estudios: Su significado en la clinica diária. Manuel Neves-e-Castro
WHI, HERS y otros estudios: Su significado en la clinica diária III Congreso Ecuatoriano de Climaterio Menopausia y Osteoporosis por Manuel Neves-e-Castro (Lisboa-Portugal) Julho, 2003 Machala The published
More information9: 3 TABLE OF CONTENTS P&T
Vol 9: No 3 TABLE OF CONTENTS Short-term Safety of Antipsychotics for Dementia 1-2 Preoperative Statins and Effects on Mortality 2-4 Hormone Replacement Therapy and Risk of Venous Thromboembolism 4-5 P&T
More informationSummary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationHT: Where do we stand after WHI?
HT: Where do we stand after WHI? Hormone therapy and cardiovascular disease risk Experimental and clinical evidence indicate that hormone therapy (HT) reduces the risk of cardiovascular disease (CVD) Women
More informationJames H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
Disclosure Estrogen Therapy After Postmenopausal Hysterectomy: Issues, Challenges, Risks/Benefits James H. Liu, M.D. Arthur H. Bill Professor Chair of Reproductive Biology Dept of Obstetrics and Gynecology
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cholesterol Treatment Trialists Collaboration.
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationHealth Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. The WHI Investigators
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin The WHI Investigators 1 Background: WHI Hormone Program Design YES N= 10,739 Conjugated equine estrogen
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationStatins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review.
ISPUB.COM The Internet Journal of Cardiovascular Research Volume 7 Number 1 Statins in the Treatment of Type 2 Diabetes Mellitus: A Systematic Review. C ANYANWU, C NOSIRI Citation C ANYANWU, C NOSIRI.
More informationHaemostasis, thrombosis risk and hormone replacement therapy
Haemostasis, thrombosis risk and hormone replacement therapy Serge Motte Brussels 13.05.17 - MY TALK TODAY The coagulation cascade and its regulation Effects of hormone replacement therapy on haemostasis
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationWEIGHING UP THE RISKS OF HRT. Department of Endocrinology Chris Hani Baragwanath Academic Hospital
WEIGHING UP THE RISKS OF HRT V. Nicolaou Department of Endocrinology Chris Hani Baragwanath Academic Hospital Background Issues surrounding post menopausal hormonal therapy (PMHT) are complex given: Increased
More informationCurrent Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes
Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes The Northern California Kaiser Permanente Diabetes Registry, 1995 1998
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationVENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?
VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK? Ayman El-Menyar (1), MD, Hassan Al-Thani (2),MD (1)Clinical Research Consultant, (2) Head of Vascular Surgery, Hamad General Hospital
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationHow HRT Hurts the Heart
How HRT Hurts the Heart Coronary artery disease (CAD) is a killer and recent studies have come up with evidence that HRT might have a role in increasing CAD among women. Why? Zaheer Lakhani, MD, FRCP For
More informationPostmenopausal hormone therapy - cardiac disease risks and benefits
Postmenopausal hormone therapy - cardiac disease risks and benefits Tomi S. Mikkola, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Helsinki, Finland Disclosures Speaker/consulting
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationNatural Hormones Replacement An Evidence and Practice Based Approach
Natural Hormones Replacement An Evidence and Practice Based Approach Andres Ruiz, PharmD, MSc, FACA President/Partner Stonegate Pharmacy PRESENTED BY THE AMERICAN COLLEGE OF APOTHECARIES 2830 SUMMER OAKS
More informationDifference between vagifem and yuvafem
Difference between vagifem and yuvafem Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, a progestin should also be considered to reduce the risk of endometrial cancer. Estrogen-alone
More informationDrug Class Review on HMG-CoA Reductase Inhibitors (Statins)
Drug Class Review on HMG-CoA Reductase Inhibitors () Final Report June 2004 Mark Helfand, MD, MPH Susan Carson, MPH Cathy Kelley, PharmD Oregon Evidence-based Practice Center Oregon Health & Science University
More informationHormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services Task Force Recommendation Statement
Clinical Review & Education JAMA US Preventive Services Task Force RECOMMENDATION STATEMENT Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women US Preventive Services
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationBreast Cancer Risk Assessment and Prevention
Breast Cancer Risk Assessment and Prevention Katherine B. Lee, MD, FACP October 4, 2017 STATISTICS More than 252,000 cases of breast cancer will be diagnosed this year alone. About 40,000 women will die
More informationTHE SAFETY CHECK LIST BEFORE STARTING HT
THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by
More informationCOMPARED WITH PLACEBO,
IGINAL INVESTIGATION Esterified Estrogen and Conjugated Equine Estrogen and the Risk of Incident Myocardial Infarction and Stroke Rozenn N. Lemaitre, PhD, MPH; Noel S. Weiss, MD, DrPH; Nicholas L. Smith,
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationSupplementary Online Content
Supplementary Online Content Gartlehner G, Patel SV, Feltner C, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Evidence Report and Systematic Review for
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More information10/11/2016. Richard J. Santen, MD. Disclosures. Key Question Regarding MHT and Breast Cancer Development. NAMS 2016 Translational Science Symposium
Richard J. Santen, MD NAMS 2016 Translational Science Symposium Risks and Benefits Related to the Breast Disclosures Current Grant Funding: Pfizer Previous Advisory Boards: Pfizer, Teva, Novo-Nordisk,
More informationStatus Update on the National Cardiovascular Prevention Guidelines - JNC 8, ATP 4, and Obesity 2
TABLE OF CONTENTS Status Update on the National Cardiovascular Prevention Guidelines 1 Drosperinone-Containing Oral Contraceptives and Venous Thromboembolism Risk 1-4 P&T Committee Formulary Action 5 Status
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationPotential dangers of hormone replacement therapy in women at high risk
ESC meeting, Stockholm, August 30, 16.30-18.00, 2010 Potential dangers of hormone replacement therapy in women at high risk Karin Schenck-Gustafsson MD, PhD, FESC Professor, Chief consultant Department
More informationIschemic heart disease is the leading cause of
The impact of C-Reactive Protein: A Look at the Most Recent Studies and Trials By Davinder S. Jassal, MD, FRCPC; and Blair O Neill, MD, FRCPC, FACC Ischemic heart disease is the world s leading killer,
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationCardiovascular Risk Reduction in Women
Cardiovascular Risk Reduction in Women Karol E. Watson, MD, PhD Assistant Professor of Medicine/ Division of Cardiology Co-director, UCLA Program in Preventive Cardiology Director, Women s Cardiovascular
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationRALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?
Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA 16917 GUIDELINES FOR USE 1. Is the request for the prevention (risk reduction) of breast cancer? If yes, continue to #2. If no, approve by HICL
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationControversies in Primary Care Pros and Cons of HRT on patients with CHD
Controversies in Primary Care Pros and Cons of HRT on patients with CHD Claire Bellone MSc Clinical Nurse Specialist Menopause Nottingham Declaration Honorariums & Sponsorship from Bayer, Novonortis, Wyeth
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCOMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH. Ross L. Prentice. Fred Hutchinson Cancer Research Center
COMMENTARY: DATA ANALYSIS METHODS AND THE RELIABILITY OF ANALYTIC EPIDEMIOLOGIC RESEARCH Ross L. Prentice Fred Hutchinson Cancer Research Center 1100 Fairview Avenue North, M3-A410, POB 19024, Seattle,
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationPresented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer
Presented by Terje R. Pedersen Oslo Disclosure: Research grants and/or speaker- / consulting fees from Merck, MSP, Astra-Zeneca, Pfizer Patients Randomized by Country 187 UK n=187 Norway n=425 Finland
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationMenopausal Hormone Therapy & Haemostasis
Menopausal Hormone Therapy & Haemostasis The Haematologist Perspective Dr. Batia Roth-Yelinek Coagulation unit Hadassah MC Menopausal Hormone Therapy & Hemostasis Hemostatic mechanism Mechanism of estrogen
More informationHormone replacement therapy in postmenopausal women
The American Journal of Surgery 188 (2004) 136 149 Review Hormone replacement therapy in postmenopausal women Edgar D. Staren, M.D., Ph.D., M.B.A.*, Shuab Omer, M.D. Department of Surgery, Medical College
More informationFor more than 50 million American women, and millions
AHA Science Advisory Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Lori Mosca, MD, PhD; Peter Collins, MD; David M.
More information